CAPR Valuation

Capricor Therapeutics Inc

Add to Watchlist

Advanced Chart

7.060

+0.58(8.951%)1D

Overview
Forecast
Valuation
Earnings

CAPR Relative Valuation

CAPR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CAPR is overvalued; if below, it's undervalued.

Historical Valuation

Capricor Therapeutics Inc (CAPR) is now in the Fair zone, suggesting that its current forward PS ratio of 4.71 is considered Fairly compared with the five-year average of -5.28. The fair price of Capricor Therapeutics Inc (CAPR) is between 6.23 to 48.88 according to relative valuation methord.

Relative Value

Fair Zone

6.23-48.88

Current Price：7.06

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.53

P/B

Median3y

9.71

Median5y

7.11

-15.93

FCF Yield

Median3y

-11.40

Median5y

-10.76

Competitors Valuation Multiple

The average P/S ratio for CAPR's competitors is 3.77, providing a benchmark for relative valuation. Capricor Therapeutics Inc Corp (CAPR) exhibits a P/S ratio of 4.71, which is 24.74% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CAPR.O

Capricor Therapeutics Inc

4.71

Average P/S: 3.77

-100.00%